Amarin appoints Jan van Heek
pharmafile | February 15, 2010 | Appointment | Research and Development, Sales and Marketing | Amarin, appointment, research and development, sales and marketing
Jan van Heek has joined Amarin’s board of directors of as a non-executive director and will also take on the role of chairman of the Dublin-based company’s audit committee.
His healthcare career spans more than 30 years in the healthcare industry and he is currently a principal and partner at advisory company BioPoint.
Prior to establishing BioPoint, Jan spent more than 18 years at Genzyme, most recently as senior advisor to the chief executive and senior management team.
He joined Genzyme in 1991 where, as executive vice president, he was largely responsible for establishing and building its worldwide therapeutics, surgical and genetic testing businesses.
“Jan van Heek has a wealth of industry experience derived from helping to build one of the world’s largest and most successful biotech companies,” commented Joseph Zakrzewski, executive chairman of Amarin. “We are very pleased he will bring this knowledge to support Amarin as we strive to create a valuable company focused on new products to improve the treatment of cardiovascular diseases.”
Prior to Genzyme, Jan held various management positions at Baxter Healthcare in Europe and the US.
Related Content
Amarin gains positive opinion from Spanish Drug Pricing Committee for national reimbursement of Vazkepa in Spain
Amarin has announced that the Spanish Drug Pricing Committee has recommended the national reimbursement of …
EMA grants marketing authorisation for Amarin’s heart attack treatment
Amarin have been granted authorisation from the EMA to market a treatment that will reduce …
Label expansion of Amarin’s Vascepa has unanimous backing of FDA advisory panel
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted in favour of expanding …